Clinical Trial Update: A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects [Phase 2]

View source ↗

Summary

Phase 2 randomized pediatric acute myeloid leukemia trial evaluating decitabine epigenetic priming with frontline induction chemotherapy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Decitabine (Decitabine)

Snippet

Sponsor: Eisai Inc. | Conditions: Acute Myelogenous Leukemia (AML) | Phase 2 | Status: WITHDRAWN